New combo therapy targets rare abdominal cancer before surgery

NCT ID NCT03361436

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests the safety and best dose of the chemotherapy drug eribulin when given with radiation therapy before surgery for retroperitoneal liposarcoma, a rare cancer that grows in the abdomen. About 15 patients will receive the combination to see how well they tolerate it and whether it helps shrink tumors before surgical removal. The goal is to find a tolerable dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Eribulin mesylate (chemotherapy drug)
What this could lead to
If successful, this could lead to a new treatment option that shrinks tumors before surgery, potentially improving outcomes for people with this rare cancer.
What could go wrong
This is a very early, small trial (Phase 1, only 15 people) focused on safety and dosing. It may not show clear benefit, and side effects from combining chemotherapy and radiation could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIPOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • OHSU Knight Cancer Institute

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.